CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Clinical significance of drug-drug interactions during HCV therapy with sofosbuvir and simeprevir in comparison to first wave protease inhibitors
DOI 10.1055/s-0034-1397218
Bibliografische Angaben
Nachweis in CareLit
Autor:innenC Höner zu Siederdissen, B Maasoumy, K Deterding, K Port, MP Manns, H Wedemeyer, M Cornberg
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe01/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Recently, it has been shown that considerable drug-drug interactions (DDI) between a first wave protease inhibitor (PI, boceprevir or telaprevir) and the regular outpatient medication affect up to 50% of hepatitis C virus (HCV) infected patients. The lately approved second wave direct-acting antiviral agents (DAA) sofosbuvir (SOF) and simeprevir (SMV) are supposed to be involved in less DDI. However, so…
Zitieren
Zitierempfehlung
C Höner zu Siederdissen, B Maasoumy, K Deterding, K Port, MP Manns, H Wedemeyer, M Cornberg (2015) Clinical significance of drug-drug interactions during HCV therapy with sofosbuvir and simeprevir in comparison to first wave protease inhibitors. Zeitschrift für Gastroenterologie (01). https://doi.org/10.1055/s-0034-1397218
Mit CareLit weiterarbeiten